D. Badesch

T. Fleming, R. Barst, D. Badesch, 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis.

R. Benza, Dave P. Miller, D. Badesch, 2013, Chest.

Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.

T. Fleming, H. Ghofrani, R. Barst, 2011, Chest.

Reassessing Patients Over Time : How To Follow Patients on Treatment

Jeffrey L. Anderson, S. Kaul, C. Tracy, 2009 .

Long-term treatment with sildenafil citrate in pulmonary arterial hypertension

T. Fleming, H. Ghofrani, R. Barst, 2008 .

Surrogate and combined end points in pulmonary arterial hypertension.

R. Benza, D. Badesch, A. Peacock, 2008, Proceedings of the American Thoracic Society.

Evidence-Based Clinical Practice Guidelines : Updated ACCP * Hypertension Medical Therapy for Pulmonary Arterial

D. Badesch, G. Simonneau, V. McLaughlin, 2007 .

Evidence-Based Clinical Practice Guidelines Hypertension: Updated ACCP Medical Therapy for Pulmonary Arterial

D. Badesch, G. Simonneau, V. McLaughlin, 2007 .

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.

R. Barst, D. Badesch, A. Frost, 2006, American journal of respiratory and critical care medicine.

Oral Therapies for PAH: State-of-the-Art and Investigational Approaches

D. Badesch, T. Bull, M. Beutz, 2006 .

Evaluation and Management of the Patient with Pulmonary Arterial Hypertension

D. Badesch, L. Rubin, 2005, Annals of Internal Medicine.

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

M. Humbert, R. Barst, D. Badesch, 2005, Thorax.

Prostanoid therapy for pulmonary arterial hypertension.

R. Barst, D. Badesch, O. Sitbon, 2004, Journal of the American College of Cardiology.

Pulmonary vascular manifestations of mixed connective tissue disease.

D. Badesch, T. Bull, K. Fagan, 2005, Rheumatic diseases clinics of North America.

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.

R. Barst, D. Badesch, A. Frost, 2006, Journal of the American College of Cardiology.

Diagnosis of pulmonary hypertension

A. Torbicki, D. Badesch, A. Frost, 2019, European Respiratory Journal.

Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey.

Dave P. Miller, D. Badesch, M. Mcgoon, 2011, Mayo Clinic proceedings.

Scleroderma and pulmonary hypertension

D. Badesch, D. Collier, K. Fagan, 2003 .

Scleroderma and pulmonary hypertension

D. Badesch, D. Collier, K. Fagan, 2003 .

Pulmonary hypertension associated with connective tissue disease.

D. Badesch, K. Fagan, 2002, Progress in cardiovascular diseases.

Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension.

B. Groves, D. Stewart, R. Barst, 1999, Circulation.

Clinical trials in pulmonary hypertension.

D. Badesch, 1997, Annual review of medicine.

Nitric oxide and prostacyclin treatment of an infant with primary pulmonary hypertension.

D. Badesch, D. Ivy, S. Abman, 1994, The American journal of cardiology.

Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group.

B. Groves, B. Brundage, C. Keller, 1997, Circulation.

Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension

G. Koch, B. Brundage, C. Keller, 1997 .

Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics

B. Groves, M. B. Perryman, D. Badesch, 2003, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.

R. Barst, D. Badesch, G. Simonneau, 2007, The Journal of rheumatology.

Inference following multiple imputation for generalized additive models: an investigation of the median p-value rule with applications to the Pulmonary Hypertension Association Registry and Colorado COVID-19 hospitalization data

Ryan A. Peterson, D. Badesch, K. Erlandson, 2022, BMC Medical Research Methodology.

Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension.

R. Marlar, D. Badesch, C. Welsh, 1996, Chest.

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.

D. Badesch, A. Frost, M. Mcgoon, 2006, Chest.

mbrisentan Therapy for ulmonary Arterial Hypertension

D. Badesch, A. Frost, G. Simonneau, 2022 .

Formulary Management of Recombinant Factor VIIa at an Academic Medical Center

D. Badesch, R. MacLaren, L. K. Golightly, 2008, The Annals of pharmacotherapy.

Genetic determinants of risk and survival in pulmonary arterial hypertension

Lisa J. Martin, Ferhaan Ahmad, W. Ouwehand, 2018, bioRxiv.

Clinical worsening in trials of pulmonary arterial hypertension: results and implications

R. Barst, D. Badesch, G. Simonneau, 2010, Current opinion in pulmonary medicine.

Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol

D. Badesch, M. Mcgoon, V. Tapson, 2009, The Journal of Rheumatology.

Pulmonary capillaritis: a possible histologic form of acute pulmonary allograft rejection.

F. Grover, M. Zamora, D. Badesch, 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Acute eosinophilic pneumonia: a hypersensitivity phenomenon?

D. Badesch, M. Schwarz, T. King, 1989, The American review of respiratory disease.

Impaired Prostacyclin Synthesis of Endothelial Cells Derived from Hypertensive Calf Pulmonary Arteries

D. Badesch, N. Voelkel, K. Stenmark, 1990 .

Imaging Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom

M. Gladwin, R. Barst, D. Badesch, 2011 .

Pulmonary hypertension in lung diseases: survey of beliefs and practice patterns.

D. Badesch, S. Nathan, J. Stoller, 2010, Respiratory medicine.

Genetic determinants of risk and survival in pulmonary arterial hypertension

Lisa J. Martin, Ferhaan Ahmad, W. Ouwehand, 2018, bioRxiv.

Pulmonary arterial hypertension and intraductal papillary mucinous neoplasms of the pancreas: A novel association?

D. Badesch, T. Bull, M. Wagh, 2021, Chest.

Insulin-like growth factor I stimulates elastin synthesis by bovine pulmonary arterial smooth muscle cells.

D. Badesch, W. Parks, K. Stenmark, 1989, Biochemical and biophysical research communications.

Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL.

R. Benza, D. Badesch, A. Frost, 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.

D. Badesch, A. Frost, A. Keogh, 2012, Chest.

Insulin-like growth factor I and pulmonary hypertension induced by continuous air embolization in sheep.

D. Badesch, K. Stenmark, B. Meyrick, 1992, American journal of respiratory cell and molecular biology.

Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension.

D. Badesch, N. Voelkel, K. Stenmark, 1989, American journal of respiratory cell and molecular biology.

Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop.

J. Knowles, D. Gail, S. Archer, 2004, Circulation.

Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.

W. Seeger, S. Rich, R. Barst, 2002, American heart journal.

Importance of right ventricular end-systolic regional wall stress in idiopathic pulmonary arterial hypertension: a new method for estimation of right ventricular wall stress.

B. Groves, R. Quaife, D. Badesch, 2006, European journal of medical research.

Hypothyroidism and Primary Pulmonary Hypertension: An Autoimmune Pathogenetic Link?

B. Groves, D. Badesch, N. Voelkel, 1993, Annals of Internal Medicine.

REVEAL REGISTRY: BASELINE CHARACTERISTICS OF THE FIRST 1,226 ENROLLED PATIENTS

G. Raskob, R. Benza, D. Badesch, 2007 .

Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.

Dave P. Miller, D. Badesch, M. Mcgoon, 2010, Chest.

A model for the objective assessment of clinical training programs: the initial application to two pulmonary medicine fellowship programs.

T. Petty, D. Badesch, M. Schwarz, 1989, The American review of respiratory disease.

Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension

S. Rich, R. Barst, D. Badesch, 2003, Journal of cardiovascular pharmacology.

Classification of Pulmonary Hypertension: History and Perspectives

D. Badesch, 2011 .

Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry

S. Duval, D. Badesch, S. Mathai, 2022, Journal of the American Heart Association.

Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry vs.

D. Glidden, N. Kolaitis, R. Benza, 2021 .

Clinical Differences and Outcomes between Methamphetamine-Associated and Idiopathic Pulmonary Arterial Hypertension in the PHAR.

D. Glidden, N. Kolaitis, R. Benza, 2020, Annals of the American Thoracic Society.

Response.

R. Benza, D. Badesch, A. Frost, 2018, Chest.

Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis.

R. Benza, Dave P. Miller, D. Badesch, 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta‐Analysis

Zhen Wang, M. Murad, Siddharth Singh, 2017, Chest.

Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.

T. Fleming, C. Strange, R. Benza, 2008, Chest.

An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

M. Gladwin, M. Telen, R. Barst, 2014, American journal of respiratory and critical care medicine.

Thyrotoxicosis as a Risk Factor for Pulmonary Arterial Hypertension

D. Badesch, L. Rubin, 2006, Annals of Internal Medicine.

Portopulmonary hypertension: a report from the US-based REVEAL Registry.

R. Dweik, Dave P. Miller, R. Barst, 2012, Chest.

Clinical risk factors for portopulmonary hypertension

J. Trotter, R. Benza, D. Badesch, 2008, Hepatology.

An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

M. Gladwin, M. Telen, R. Barst, 2014, American journal of respiratory and critical care medicine.

Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry

D. Badesch, D. Ivy, S. Mathai, 2021, Pulmonary circulation.

Bosentan therapy for pulmonary arterial hypertension.

R. Barst, D. Badesch, A. Frost, 2002, The New England journal of medicine.

CORRELATION OF ACUTE PROSTACYCLIN RESPONSE IN PRIMARY (UNEXPLAINED) PULMONARY HYPERTENSION WITH EFFICACY OF TREATMENT WITH CALCIUM CHANNEL BLOCKERS AND SURVIVAL

B. Groves, D. Badesch, N. Voelkel, 1993 .

Exercise‐Induced Pulmonary Hypertension: Translating Pathophysiological Concepts Into Clinical Practice

S. Rajagopalan, D. Badesch, R. Naeije, 2018, Chest.

Sildenafil for COPD: A Randomized Crossover Trial

D. Badesch, T. Bull, 2012, COPD.

Anticoagulation in Pulmonary Arterial Hypertension

D. Badesch, S. Pugliese, Jeffrey C. Robinson, 2016, Current Hypertension Reports.

The past, present, and future of lung transplantation.

F. Grover, M. Zamora, D. Badesch, 1997, American journal of surgery.

Timed Response to Inhaled Nitric Oxide in Pulmonary Hypertension

Joseph D. Kay, J. Messenger, J. Carroll, 2014, Pulmonary circulation.

Obesity in Pulmonary Arterial Hypertension

D. Badesch, S. Mathai, O. Shlobin, 2021 .

The study of risk in pulmonary arterial hypertension

M. Humbert, D. Badesch, G. Simonneau, 2012, European Respiratory Review.

Colon perforation after lung transplantation.

F. Grover, M. Zamora, D. Badesch, 1996, The Annals of thoracic surgery.

Erratum: "Survival with first-line bosentan in patients with primary pulmonary hypertension" (European Respiratory Journal (2005) vol. 25 (244-249))

R. Barst, D. Badesch, G. Simonneau, 2005 .

Sotatercept for the Treatment of Pulmonary Arterial Hypertension.

M. Humbert, S. Manimaran, D. Badesch, 2021, The New England journal of medicine.

Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension.

A. Torbicki, D. Badesch, D. Khanna, 2019, Seminars in arthritis and rheumatism.

Prediction of patient outcomes through social determinants of health: The Pulmonary Hypertension Association Registry (PHAR) evaluation

D. Badesch, T. DeMarco, O. Shlobin, 2022, Pulmonary circulation.

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ILOPROST INHALATION AS ADD-ON THERAPY TO BOSENTAN IN PULMONARY ARTERIAL HYPERTENSION (PAH)

R. Barst, D. Badesch, A. Frost, 2005 .

ARIES-1: A PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AMBRISENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

D. Badesch, A. Frost, M. Mcgoon, 2006 .

Validation Of The French Pulmonary Hypertension Network Equation To Estimate Survival: A REVEAL Analysis

M. Humbert, R. Benza, D. Badesch, 2012, ATS 2012.

The Potential for Therapeutic Misconception in Pulmonary Arterial Hypertension Clinical Trials: A Case-Based Discussion

D. Badesch, T. Bull, Deborah H. McCollister, 2010 .

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study

D. Badesch, A. Frost, G. Simonneau, 2001, The Lancet.

Prediction of Health-Related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR).

D. Badesch, M. Simon, O. Shlobin, 2020, American journal of respiratory and critical care medicine.

Obesity in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR).

D. Badesch, S. Mathai, M. Simon, 2020, Annals of the American Thoracic Society.

Survival in Pulmonary Hypertension Registries: Response

D. Badesch, M. Mcgoon, L. Parsons, 2011 .

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

M. Humbert, H. Ghofrani, S. Manimaran, 2022, European Respiratory Journal.

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

B. Groves, B. Brundage, C. Keller, 1996, The New England journal of medicine.

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

G. Raskob, R. Benza, R. Barst, 2010, Chest.

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)

R. Benza, D. Badesch, N. Hill, 2022, Pulmonary circulation.

397: REVEAL Registry: Pediatric IPAH Versus Pediatric Pulmonary Vascular Disease Associated with Congenital Heart Disease

G. Raskob, R. Benza, R. Barst, 2009 .

708: REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Pulmonary Vascular Disease Associated with Congenital Heart Disease

G. Raskob, R. Benza, R. Barst, 2009 .

228: REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Idiopathic Pulmonary Arterial Hypertension

G. Raskob, R. Benza, R. Barst, 2009 .

A COMPARISON OF REVEAL REGISTRY DEMOGRAPHIC DATA WITH OTHER/PRIOR REGISTRIES OF PULMONARY ARTERIAL HYPERTENSION (PAH)

G. Raskob, R. Benza, R. Barst, 2008 .

Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients with Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial.

M. Gladwin, R. Woolson, R. Barst, 2009 .

Cicletanine in pulmonary arterial hypertension (PAH): Results from a phase 2 randomized placebo-controlled trial

D. Badesch, M. Gomberg-Maitland, A. Keogh, 2012 .

Cardiac catheterization of patients with pulmonary hypertension

B. Groves, D. Badesch, T. Bull, 2011 .

Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status.

J. Rumsfeld, D. Badesch, F. Masoudi, 2010, Psychosomatics.

Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease

Stuart Rich, Srinivas Murali, C. Elliott, 2000, Annals of Internal Medicine.

Use Of The REVEAL Pulmonary Arterial Hypertension (PAH) Risk Score Calculator In Newly Diagnosed Patients

R. Benza, D. Badesch, A. Frost, 2010, ATS 2010.

RATIONALE AND DESIGN OF THE PRIMEX TRIAL: A STUDY OF 2 DOSES OF ORAL CXA-10 IN PULMONARY ARTERIAL HYPERTENSION (PAH)

M. Gladwin, R. Benza, D. Badesch, 2020 .

REVEAL Registry: Impact of Clinical Worsening on Three-Year Outcomes in Pulmonary Arterial Hypertension

R. Benza, D. Badesch, A. Frost, 2010 .

External validation of the French predictive model to estimate PAH survival: A REVEAL analysis

M. Humbert, R. Benza, D. Badesch, 2012 .

External validation of the REVEAL risk score calculator for PAH survival: A French pulmonary hypertension network analysis

M. Humbert, R. Benza, D. Badesch, 2012 .

Risk Factors for Death in 632 Patients with Sickle Cell Anemia in the United States and United Kingdom

M. Gladwin, R. Barst, D. Badesch, 2012 .

Sildenafil citrate therapy for pulmonary arterial hypertension.

T. Fleming, A. Torbicki, A. Branzi, 2005, The New England journal of medicine.

Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines

D. Mccrory, R. Barst, D. Badesch, 2004 .

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

D. Mccrory, R. Barst, D. Badesch, 2004, Chest.

Potassium and phosphorus repletion in hospitalized patients: implications for clinical practice and the potential use of healthcare information technology to improve prescribing and patient safety*

Brian A Hemstreet, Nancy M. Stolpman, D. Badesch, 2006, Current medical research and opinion.

Magnesium toxicity as a cause of hypotension and hypoventilation. Occurrence in patients with normal renal function.

D. Badesch, J. Marini, W. Stone, 1985, Archives of Internal Medicine.

Beraprost therapy for pulmonary arterial hypertension.

K. Wasserman, S. Rich, R. Barst, 2003, Journal of the American College of Cardiology.

Insulin‐Like growth factor I and protein kinase C activation stimulate pulmonary artery smooth muscle cell proliferation through separate but synergistic pathways

D. Badesch, N. Voelkel, K. Stenmark, 1990, Journal of cellular physiology.

End points and clinical trial design in pulmonary arterial hypertension.

T. Fleming, W. Seeger, D. Badesch, 2004, Journal of the American College of Cardiology.

United States Pulmonary Hypertension Scientific Registry (USPHSR): Baseline Characteristics.

W. Chung, R. Simms, R. Benza, 2020, Chest.

Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension

Lisa J. Martin, Ferhaan Ahmad, W. Chung, 2019, Genome Medicine.

United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications

W. Chung, R. Benza, D. Badesch, 2019, Pulmonary circulation.

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis

Lisa J. Martin, Keith A. Marsolo, Ferhaan Ahmad, 2018, bioRxiv.

Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension

Lisa J. Martin, Ferhaan Ahmad, W. Chung, 2019, Genome Medicine.

Surrogate Markers for Pulmonary Hypertension May Inform Prognosis in Lung Cancer

D. Badesch, L. Forbes, S. Gu, 2021, American journal of respiratory and critical care medicine.

Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.

F. Grover, M. Zamora, D. Badesch, 1994, Transplantation proceedings.

ACCF/AHA Expert Conseusus Document

Jeffrey L. Anderson, S. Kaul, C. Tracy, 2009 .

Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom

M. Gladwin, R. Barst, D. Badesch, 2011, Circulation.

Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)

Christopher S Coffey, C. Coffey, R. Benza, 2010, Circulation.

Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status.

J. Rumsfeld, D. Badesch, F. Masoudi, 2010, Psychosomatics.

Diagnosis and assessment of pulmonary arterial hypertension.

Horst Olschewski, Adam Torbicki, A. Torbicki, 2009, Journal of the American College of Cardiology.

The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.

R. Benza, D. Badesch, A. Frost, 2012, Chest.

Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study.

D. Badesch, R. Schrier, S. Bansal, 2009, Contemporary clinical trials.

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

T. Fleming, R. Barst, D. Badesch, 2008, Annals of internal medicine.

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2

B. Wiens, H. Ghofrani, D. Badesch, 2008, Circulation.

Update on pulmonary arterial hypertension research: proceedings from a meeting of experts

R. Benza, D. Badesch, A. Frost, 2018, Current medical research and opinion.

EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR

D. Badesch, T. DeMarco, S. Mathai, 2020, European Respiratory Journal.

Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting

D. Badesch, K. Chin, R. Frantz, 2020, Pulmonary circulation.

Psychometric Validation of the Pulmonary Arterial Hypertension‐Symptoms and Impact (PAH‐SYMPACT) Questionnaire: Results of the SYMPHONY Trial

D. Badesch, M. Gomberg-Maitland, A. Fischer, 2018, Chest.

Depression: Beyond Description As an Important Comorbidity in Pulmonary Arterial Hypertension—The Next Steps

D. Badesch, Deborah H. McCollister, P. Weintraub, 2012 .

Definitions and diagnosis of pulmonary hypertension.

Toru Satoh, D. Badesch, M. Wilkins, 2013, Journal of the American College of Cardiology.

ACCP Evidence-Based Clinical Practice Guidelines

D. Mccrory, R. Barst, D. Badesch, 2004 .

Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report

D. Badesch, V. Steen, E. Bossone, 2019, Chest.

Therapy for Pulmonary Arterial Hypertension in Adults

D. Badesch, V. Steen, E. Bossone, 2019 .

Pulmonary function testing in patients with pulmonary arterial hypertension.

Z. Jing, D. Badesch, L. Pan, 2009, Respiratory medicine.

Survival with first-line bosentan in patients with primary pulmonary hypertension

R. Barst, D. Badesch, G. Simonneau, 2005, European Respiratory Journal.

Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Randomized, Placebo-controlled Trial.

A. Sweatt, H. Maecker, R. Domsic, 2021, American journal of respiratory and critical care medicine.

PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH)

M. Humbert, R. Zeldin, D. Badesch, 2019, Pulmonary hypertension.

The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.

G. Raskob, R. Benza, R. Barst, 2011, Chest.

Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom

M. Gladwin, R. Barst, D. Badesch, 2014, PloS one.

ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.

D. Badesch, A. Frost, M. Mcgoon, 2009, Cardiovascular therapeutics.

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.

D. Badesch, M. Gomberg-Maitland, K. Olsson, 2023, The New England journal of medicine.

Validation of two predictive models for survival in pulmonary arterial hypertension

M. Humbert, R. Benza, R. Barst, 2015, European Respiratory Journal.

Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry

R. Benza, D. Badesch, S. Mathai, 2020, Pulmonary circulation.

Baseline and Serial Brain Natriuretic Peptide Level Predicts 5‐Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry

R. Benza, D. Badesch, A. Frost, 2018, Chest.

Temporal trends and drug exposures in pulmonary hypertension: an American experience.

L. Abenhaim, B. Strom, S. Rich, 2006, American heart journal.

Ambrisentan therapy for pulmonary arterial hypertension.

D. Badesch, A. Frost, M. Mcgoon, 2005, Journal of the American College of Cardiology.

Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report.

H. Palevsky, R. Yung, S. Rich, 2014, Chest.

Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.

H. Tighiouart, J. Knowles, D. Rabinowitz, 2009, American journal of respiratory and critical care medicine.

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.

D. Badesch, A. Frost, G. Simonneau, 2003, Chest.

Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension

D. Badesch, A. Frost, G. Simonneau, 2002 .

Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study

R. Barst, D. Badesch, A. Frost, 2014, Chest.

Acute Hemodynamic Effects of Iloprost in Primary (Unexplained) Pulmonary Hypertension

B. Groves, D. Badesch, N. Voelkel, 1994 .

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study.

D. Badesch, A. Frost, G. Simonneau, 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

R. Kronmal, N. Kolaitis, R. Benza, 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Sex hormone exposure and reproductive factors in pulmonary arterial hypertension: a case–control study

D. Badesch, J. Loyd, E. Brittain, 2020, Pulmonary circulation.

Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry

D. Badesch, D. Ivy, S. Mathai, 2020, Pulmonary circulation.

152 Post-Marketing Hepatic Safety Profile of Ambrisentan in Patients with Pulmonary Arterial Hypertension – 4 Year Update

D. Badesch, M. Allard, M. Littman, 2012 .

Independent ventilation and ECMO for severe unilateral pulmonary edema after SLT for primary pulmonary hypertension.

M. Zamora, D. Badesch, D. Fullerton, 1995, Chest.

Pulmonary artery compliance in different forms of pulmonary hypertension

R. Benza, D. Badesch, S. Mathai, 2023, Heart.

Enhanced growth capacity of neonatal pulmonary artery smooth muscle cells in vitro: Dependence on cell size, time from birth, insulin‐like growth factor I, and auto‐activation of protein Kinase C

D. Badesch, K. Stenmark, E. Dempsey, 1994, Journal of cellular physiology.

A fluid challenge test for the diagnosis of occult heart failure.

M. Humbert, D. Badesch, R. Naeije, 2020, Chest.

Comparison of Body Habitus in Patients With Pulmonary Arterial Hypertension Enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management With Normative Values From the National Health and Nutrition Examination Survey

D. Badesch, M. Mcgoon, R. Safford, 2011 .

AMBRISENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION: A COMPARISON BY PAH ETIOLOGY

D. Badesch, 2007 .

SITAXSENTAN, A SELECTIVE ENDOTHELIN-A RECEPTOR ANTAGONIST, IMPROVES EXERCISE CAPACITY IN PULMONARY ARTERIAL HYPERTENSION (PAH) ASSOCIATED WITH CONNECTIVE TISSUE DISEASE (CTD)

R. Barst, D. Badesch, R. Naeije, 2005 .

Development of a new patient-reported outcome (PRO) instrument for pulmonary arterial hypertension (PAH): The pulmonary arterial hypertension–symptoms and impact (PAH-SYMPACT) questionnaire

I. Wiklund, D. Badesch, Deborah H. McCollister, 2013 .

D. Badesch, S. Mathai, J. Ryan, 2021, medRxiv.

Serotonin transporter polymorphisms in patients with portopulmonary hypertension.

J. Knowles, J. Trotter, R. Benza, 2009, Chest.

Donor-to-host transmission of Mycoplasma hominis in lung allograft recipients.

F. Grover, F. Fang, D. Badesch, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.

D. Badesch, N. Voelkel, R. Tuder, 1999, American journal of respiratory and critical care medicine.

Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.

B. Groves, D. Badesch, N. Voelkel, 1994, The American journal of pathology.

Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium.

B. Groves, R. Quaife, D. Badesch, 1997, The Journal of clinical investigation.

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension A Double-Blind Placebo-controlled Clinical Trial

M. Yigla, Akram Khan, C. Bao, 2020 .

Psychometric Validation of the Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT®) Questionnaire

D. Badesch, M. Gomberg-Maitland, A. Fischer, 2016 .

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial

M. Yigla, Akram Khan, C. Bao, 2019, American journal of respiratory and critical care medicine.

Definitions and diagnosis of pulmonary hypertension.

D. Badesch, M. Wilkins, M. Hoeper, 2013, Journal of the American College of Cardiology.

Transmission of Lactobacillus pneumonia by a transplanted lung.

F. Grover, M. Zamora, D. Badesch, 1994, The Annals of thoracic surgery.

Autoimmunity and pulmonary hypertension: a perspective

D. Badesch, N. Voelkel, M. Nicolls, 2005, European Respiratory Journal.

Surrogate and combined end points in pulmonary arterial hypertension.

R. Benza, D. Badesch, A. Peacock, 2008, Proceedings of the American Thoracic Society.

Clinical risk factors for portopulmonary hypertension

J. Trotter, R. Benza, D. Badesch, 2008, Hepatology.

ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.

D. Badesch, A. Frost, M. Mcgoon, 2012, Cardiovascular therapeutics.

End points and clinical trial design in pulmonary arterial hypertension.

T. Fleming, W. Seeger, D. Badesch, 2004, Journal of the American College of Cardiology.

The pressure-overloaded right ventricle in pulmonary hypertension.

R. Quaife, D. Badesch, W. Abraham, 1998, Chest.

Primary pulmonary hypertension, Castleman's disease and human herpesvirus‐8

D. Badesch, N. Voelkel, M. Geraci, 2003, European Respiratory Journal.

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

D. Badesch, D. Langleben, R. Bourge, 2000, Annals of internal medicine.

Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial

D. Badesch, M. Gomberg-Maitland, K. Olsson, 2023, European Respiratory Journal.

Long-Term Effects of Sotatercept on Right Ventricular Function: Results From the PULSAR Study.

S. Manimaran, D. Badesch, M. Gomberg-Maitland, 2023, JACC. Heart failure.

Hyperuricemia in severe pulmonary hypertension.

B. Groves, D. Badesch, N. Voelkel, 2000, Chest.

Current Therapeutic Options in Severe Pulmonary Hypertension

B. Groves, D. Badesch, 1994 .